Skip to main content
logo
Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
8.49
-0.25 (-2.86%)
Nov 2, 2026, 4:00 PM EST - Market closed

Benitec Biopharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Revenue
---0.080.07
Revenue
---0.080.07
Revenue Growth
---2.74%23.73%
Cost of Revenue
---0.11-0.01
Gross Profit
--0.110.080.06
Selling, General & Admin
27.823.436.996.386.65
Research & Development
23.3918.3315.6112.7711.27
Operating Expenses
51.1941.7722.619.1617.92
Operating Income
-51.19-41.77-22.49-19.08-17.85
Interest Expense
----0.03-0.03
Interest & Investment Income
5.573.290.9--
Currency Exchange Gain (Loss)
0.12-0.070.04-0.42-0.23
Other Non Operating Income (Expenses)
-0.04-0.13-0.2-0.03-0.08
EBT Excluding Unusual Items
-45.55-38.68-21.75-19.56-18.2
Gain (Loss) on Sale of Investments
---0-0-0.01
Other Unusual Items
-0.76---
Pretax Income
-45.55-37.92-21.75-19.56-18.21
Net Income
-45.55-37.92-21.75-19.56-18.21
Preferred Dividends & Other Adjustments
--0.62--
Net Income to Common
-45.55-37.92-22.37-19.56-18.21
Net Income Growth
-----
Shares Outstanding (Basic)
47361810
Shares Outstanding (Diluted)
47361810
Shares Change
28.58%97.17%1225.17%188.30%90.24%
EPS (Basic)
-0.98-1.05-1.22-14.12-37.88
EPS (Diluted)
-0.98-1.05-1.22-14.12-37.88
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
-16.62-23.61-19.58-18.01-15.91
Free Cash Flow Per Share
-0.36-0.65-1.07-13.00-33.10
Gross Margin
---100.00%87.67%
Operating Margin
----25441.33%-24457.53%
Profit Margin
----26082.67%-24942.47%
Free Cash Flow Margin
----24017.33%-21797.26%
EBITDA
-51.13-41.7-22.4-18.95-17.69
D&A For EBITDA
0.060.070.090.140.17
EBIT
-51.19-41.77-22.49-19.08-17.85
SEC Filings: 10-K · 10-Q